{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:36:29Z","timestamp":1787164589020,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1136\/ard.2007.083071","type":"journal-article","created":{"date-parts":[[2008,2,4]],"date-time":"2008-02-04T20:34:17Z","timestamp":1202157257000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"title":["Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol"],"prefix":"10.1016","volume":"68","author":[{"given":"M K","family":"Reinders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E N","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T L Th A","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Delsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E N","family":"Griep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A F J","family":"van de Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R B J","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.083071_bib1","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/kel071","article-title":"Effectiveness of interventions for the treatment of acute and prevention of recurrent gout\u2014a systematic review.","volume":"45","author":"Sutaria","year":"2006","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.083071_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(94)80011-1","article-title":"Hepatic injury caused by benzbromarone.","volume":"20","author":"Van der Klauw","year":"1994","journal-title":"J Hepatol"},{"key":"10.1136\/ard.2007.083071_bib3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0168-8278(00)80263-9","article-title":"Fatal fulminant hepatic failure associated with benzbromarone.","volume":"32","author":"Wagayama","year":"2000","journal-title":"J Hepatol"},{"key":"10.1136\/ard.2007.083071_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1046\/j.1440-1746.2002.02692.x","article-title":"Fulminant hepatic failure associated with benzbromarone treatment: a case report.","volume":"17","author":"Arai","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1136\/ard.2007.083071_bib5","first-page":"701","article-title":"Ten years\u2019 experience with benzbromarone in the management of gout and hyperuricaemia.","volume":"59","author":"Masbernard","year":"1981","journal-title":"S Afr Med J"},{"key":"10.1136\/ard.2007.083071_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2165\/00002018-199411040-00004","article-title":"Risks and benefits of drugs used in the management and prevention of gout.","volume":"11","author":"Conaghan","year":"1994","journal-title":"Drug Saf"},{"key":"10.1136\/ard.2007.083071_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout.","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083071_bib8","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Gout.","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl Med J"},{"key":"10.1136\/ard.2007.083071_bib9","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1001\/jama.289.21.2857","article-title":"Gout.","volume":"289","author":"Rott","year":"2003","journal-title":"JAMA"},{"key":"10.1136\/ard.2007.083071_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.bor.0000162060.25895.a5","article-title":"Recent advances in the management of gout and hyperuricemia.","volume":"17","author":"Wortmann","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2007.083071_bib11","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d?","volume":"22","author":"Jansen","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.083071_bib12","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083071_bib13","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083071_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083071_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data.","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard.2007.083071_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment.","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2007.083071_bib17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083071_bib18","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout.","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.083071_bib19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","article-title":"Synovial fluid analysis for diagnosis of intercritical gout.","volume":"131","author":"Pascual","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083071_bib20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout.","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083071_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1136\/ard.2007.083071_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1136\/ard.2007.083071_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(90)90097-W","article-title":"Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates.","volume":"89","author":"Kaehny","year":"1990","journal-title":"Am J Med"},{"key":"10.1136\/ard.2007.083071_bib24","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout.","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.083071_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083071_bib26","first-page":"S40","article-title":"Efficacy of benzbromarone compared to allopurinol in lowering serum urate level in hyperuricemic patients.","volume":"85","author":"Hanvivadhanakul","year":"2002","journal-title":"J Med Assoc Thai"},{"key":"10.1136\/ard.2007.083071_bib27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jpba.2007.08.002","article-title":"A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection.","volume":"45","author":"Reinders","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.1136\/ard.2007.083071_bib28","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.","volume":"26","author":"Reinders","year":"2007","journal-title":"Clin Rheum"},{"key":"10.1136\/ard.2007.083071_bib29","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083071_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","article-title":"Allopurinol in the treatment of gout.","volume":"64","author":"Rundles","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083071_bib31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokin"},{"key":"10.1136\/ard.2007.083071_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review.","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1136\/ard.2007.083071_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bmj.312.7024.173","article-title":"Allopurinol, erythema multiforme, and renal insufficiency.","volume":"312","author":"Kumar","year":"1996","journal-title":"BMJ"},{"key":"10.1136\/ard.2007.083071_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/clin.1994.1022","article-title":"Cell-mediated immunity in allopurinol-induced hypersensitivity.","volume":"70","author":"Braden","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1136\/ard.2007.083071_bib35","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1136\/ard.2007.083071_bib36","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art.","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1136\/ard.2007.083071_bib37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.40.3.245","article-title":"Acute adverse reactions attributed to allopurinol in hospitalised patients.","volume":"40","author":"McInnes","year":"1981","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083071_bib38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt1978235598","article-title":"Allopurinol kinetics.","volume":"23","author":"Hande","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard.2007.083071_bib39","first-page":"82","article-title":"Diuretic and non-diuretic actions of furosemide: effects of probenecid.","volume":"15","author":"Walshaw","year":"1992","journal-title":"Clin Invest Med"},{"key":"10.1136\/ard.2007.083071_bib40","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/ard.25.Suppl_6.623","article-title":"Comparison of allopurinol and probenecid.","volume":"25","author":"Scott","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083071_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/archinte.1955.00250070099012","article-title":"Probenecid (Benemid); its uses and side-effects in 2,502 patients.","volume":"95","author":"Boger","year":"1955","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2007.083071_bib42","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083071_bib43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout.","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard.2007.083071_bib44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","article-title":"Rasburicase treatment in severe tophaceous gout; a novel therapeutic option.","volume":"25","author":"Moolenburgh","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2007.083071_bib45","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2007.083071_bib46","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083071_bib47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00173.x","article-title":"The impact of gout on work absence and productivity.","volume":"10","author":"Kleinman","year":"2007","journal-title":"Value Health"},{"key":"10.1136\/ard.2007.083071_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11926-001-0048-8","article-title":"Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.","volume":"3","author":"Fam","year":"2001","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard.2007.083071_bib49","first-page":"U1528","article-title":"Benzbromarone therapy in management of refractory gout.","volume":"118","author":"Kumar","year":"2005","journal-title":"N Z Med J"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724426587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724426587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.083071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:17:50Z","timestamp":1737245870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724426587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0003496724426587"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.083071","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.083071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 2009 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}